Literature DB >> 11814405

Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture.

Wenbo Zhou1, Jerome Schaack, W Michael Zawada, Curt R Freed.   

Abstract

Mutations in the alpha-synuclein gene have been linked to rare cases of familial Parkinson's disease (PD). Alpha-synuclein is a major component of Lewy bodies (LB), a pathological hallmark of PD. Transgenic mice and Drosophila expressing either wild-type or mutant human alpha-synuclein develop motor deficits, LB-like inclusions in some neurons, and neuronal degeneration. However, the relationship between abnormal aggregates of alpha-synuclein and human dopamine (DA) neuron degeneration remains unclear. In this report, we have investigated the influence of alpha-synuclein expression on DA neurons in primary culture of embryonic human mesencephalon. Two days after culture, human DA cells were transduced with wild-type or mutant human (Ala(53)Thr) alpha-synuclein adenoviruses and maintained for 5 days. Overexpression of mutant and wild-type human alpha-synuclein resulted in 49% (P<0.01) and 27% (P<0.05) loss of DA neurons, respectively, while not affecting viability of other cells in the culture. Overexpression of rat alpha-synuclein or GFP (green fluorescent protein) had no effect on DA neuron survival. Cytoplasmic inclusions of alpha-synuclein were detected immunohistochemically in DA cells transduced with mutant human alpha-synuclein, but not wild-type alpha-synuclein. These results show that overexpression of human alpha-synuclein, particularly the mutant form, can cause human DA neuron death, suggesting that alpha-synuclein may have a primary role in the pathogenesis of PD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11814405     DOI: 10.1016/s0006-8993(01)03292-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  31 in total

1.  Neuroprotective upregulation of endogenous α-synuclein precedes ubiquitination in cultured dopaminergic neurons.

Authors:  R E J Musgrove; A E King; T C Dickson
Journal:  Neurotox Res       Date:  2010-07-09       Impact factor: 3.911

2.  The oxysterol 27-hydroxycholesterol regulates α-synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liver X receptors and estrogen receptors--relevance to Parkinson's disease.

Authors:  Gurdeep Marwarha; Turk Rhen; Trevor Schommer; Othman Ghribi
Journal:  J Neurochem       Date:  2011-10-24       Impact factor: 5.372

3.  Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions.

Authors:  Wenbo Zhou; Chunmei Long; Stephen H Reaney; Donato A Di Monte; Anthony L Fink; Vladimir N Uversky
Journal:  Biochim Biophys Acta       Date:  2009-12-21

Review 4.  Alpha-synuclein and dopamine metabolism.

Authors:  Shun Yu; Kenji Uéda; Piu Chan
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

Review 5.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09

6.  Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells.

Authors:  Jun Tang Guo; An Qi Chen; Qi Kong; Hua Zhu; Chun Mei Ma; Chuan Qin
Journal:  Cell Mol Neurobiol       Date:  2007-11-06       Impact factor: 5.046

Review 7.  Neurobiology of alpha-synuclein.

Authors:  Kostas Vekrellis; Hardy J Rideout; Leonidas Stefanis
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

8.  Neuroprotective Effects of Paeoniflorin on 6-OHDA-Lesioned Rat Model of Parkinson's Disease.

Authors:  Xiao-Su Gu; Fen Wang; Cai-Yi Zhang; Cheng-Jie Mao; Jing Yang; Ya-Ping Yang; Sha Liu; Li-Fang Hu; Chun-Feng Liu
Journal:  Neurochem Res       Date:  2016-07-22       Impact factor: 3.996

Review 9.  Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases.

Authors:  Latha Devi; Hindupur K Anandatheerthavarada
Journal:  Biochim Biophys Acta       Date:  2009-07-18

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.